MacroGenics to Present at H.C. Wainwright 27th Annual Global Investment Conference
MGNX(NASDAQ:MGNX) ROCKVILLE, MD, Sept. 02, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced that MacroGenics’ President & Chief Executive Officer, Eric Risser, will present at the H.C. Wainwright 27th Annual Global Investment Conference on Monday, September 8, 2025, at 11:30am ET in New York, NY.
MacroGenics Reports Second Quarter 2025 Financial Results and Highlights Key Strategic Priorities
MGNXROCKVILLE, Md., Aug. 14, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today reported financial results for the second quarter ended June 30, 2025, and highlighted recent corporate progress.
MacroGenics Appoints Eric Risser as President and Chief Executive Officer
MGNXROCKVILLE, MD, Aug. 13, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company developing innovative antibody-based therapeutics for the treatment of cancer, today announced that effective as of August 13, 2025, Eric Risser has been appointed President, Chief Executive Officer and to the Board of Directors. Mr. Risser has served as Chief Operating Officer at MacroGenics since 2022, overseeing several key company functions and has led the Company’s corporate development efforts, which have generated over $1.6 billion in non-dilutive capital since inception. Mr. Risser succeeds Scott Koenig, M.D., Ph.D. who is stepping down after serving as President and Chief Executive Officer for the past 24 years.
MacroGenics Forged A ZYNYZ Royalty Purchase Deal With Sagard Healthcare Partners For $70M Upfront Payment, Extending Cash Runway Through First Half Of 2027
MGNX4 Analysts Assess Macrogenics: What You Need To Know
MGNXB. Riley Securities Maintains Neutral on Macrogenics, Lowers Price Target to $3
MGNXStifel Maintains Hold on Macrogenics, Lowers Price Target to $5
MGNXBarclays Maintains Overweight on Macrogenics, Lowers Price Target to $3
MGNXMacrogenics Q1 EPS $(0.65) Beats $(0.76) Estimate, Sales $13.19M Beat $6.17M Estimate
MGNXA Look at Macrogenics's Upcoming Earnings Report
MGNXHC Wainwright & Co. Maintains Neutral on Macrogenics, Lowers Price Target to $2
MGNXMacroGenics 2024 EPS $(1.07) Down From $(0.15) YoY
MGNXHC Wainwright & Co. Reiterates Neutral on Macrogenics, Maintains $4 Price Target
MGNXMacrogenics Q3 EPS $0.90 Beats $0.21 Estimate, Sales $110.71M Beat $76.11M Estimate
MGNXMacrogenics Earnings Preview
MGNXHC Wainwright & Co. Maintains Buy on Macrogenics, Lowers Price Target to $10
MGNX6 Analysts Have This to Say About Macrogenics
MGNXMacrogenics (NASDAQ:MGNX) has observed the following analyst ratings within the last quarter:
Guggenheim Downgrades Macrogenics to Neutral
MGNXHC Wainwright & Co. Maintains Buy on Macrogenics, Lowers Price Target to $35
MGNXSVB Leerink Maintains Outperform on Macrogenics, Lowers Price Target to $15
MGNXMacrogenics: Q1 Earnings Insights
MGNXMacrogenics (NASDAQ:MGNX) reported its Q1 earnings results on Tuesday, May 3, 2022 at 04:00 PM.
Here's what investors need to know about the announcement.
Earnings
Macrogenics missed estimated earnings by 25.58%, reporting an EPS of $-1.08 versus an estimate of $-0.86.
Macrogenics Q1 EPS $(1.08) Misses $(0.86) Estimate, Sales $11.10M Miss $21.48M Estimate
MGNXMacrogenics's Earnings Outlook
MGNXMacrogenics (NASDAQ:MGNX) is set to give its latest quarterly earnings report on Tuesday, 2022-05-03. Here's what investors need to know before the announcement.
Analysts estimate that Macrogenics will report an earnings per share (EPS) of $-0.86.
